Allosteric modulation of adenosine receptors. 2011

Anikó Göblyös, and Ad P Ijzerman
Leiden/Amsterdam Center for Drug Research, Division of Medicinal Chemistry, Leiden, The Netherlands.

Allosteric ligands for G protein-coupled receptors (GPCRs) may alter receptor conformations induced by an orthosteric ligand. These modulators can thus fine-tune classical pharmacological responses. In this review we will describe efforts to synthesize and characterize allosteric modulators for one particular GPCR subfamily, the adenosine receptors. There are four subtypes of these receptors: A(1), A(2A), A(2B) and A(3). Allosteric enhancers for the adenosine A(1) receptor may have anti-arrythmic and anti-lipolytic activity. They may also act as analgesics and neuroprotective agents. A(3) allosteric enhancers are thought to be beneficial in ischemic conditions or as antitumor agents. We will summarize recent developments regarding the medicinal chemistry of such compounds. Most data have been and are published about the adenosine A(1) and A(3) receptor, whereas limited or no information is available for the A(2A) and A(2B) receptor, respectively. Receptor mutation studies are also discussed, as they may shed light on the localization of the allosteric binding sites. This article is part of a Special Issue entitled: "Adenosine Receptors".

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000494 Allosteric Regulation The modification of the reactivity of ENZYMES by the binding of effectors to sites (ALLOSTERIC SITES) on the enzymes other than the substrate BINDING SITES. Regulation, Allosteric,Allosteric Regulations,Regulations, Allosteric
D000495 Allosteric Site A site on an enzyme which upon binding of a modulator, causes the enzyme to undergo a conformational change that may alter its catalytic or binding properties. Allosteric Sites,Site, Allosteric,Sites, Allosteric
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D018047 Receptors, Purinergic P1 A class of cell surface receptors that prefer ADENOSINE to other endogenous PURINES. Purinergic P1 receptors are widespread in the body including the cardiovascular, respiratory, immune, and nervous systems. There are at least two pharmacologically distinguishable types (A1 and A2, or Ri and Ra). Adenosine Receptors,P1 Purinoceptors,Purinergic P1 Receptors,Receptors, Adenosine,Adenosine Receptor,P1 Purinoceptor,Receptor, Purinergic P1,P1 Receptor, Purinergic,P1 Receptors, Purinergic,Purinergic P1 Receptor,Purinoceptor, P1,Purinoceptors, P1,Receptor, Adenosine

Related Publications

Anikó Göblyös, and Ad P Ijzerman
June 2005, Mini reviews in medicinal chemistry,
Anikó Göblyös, and Ad P Ijzerman
February 2022, International journal of molecular sciences,
Anikó Göblyös, and Ad P Ijzerman
January 2016, Frontiers in immunology,
Anikó Göblyös, and Ad P Ijzerman
September 2011, British journal of pharmacology,
Anikó Göblyös, and Ad P Ijzerman
June 2005, Mini reviews in medicinal chemistry,
Anikó Göblyös, and Ad P Ijzerman
January 2023, Frontiers in endocrinology,
Anikó Göblyös, and Ad P Ijzerman
September 2000, Biochemical pharmacology,
Anikó Göblyös, and Ad P Ijzerman
August 2001, Anesthesiology,
Anikó Göblyös, and Ad P Ijzerman
August 2010, Pharmaceuticals (Basel, Switzerland),
Anikó Göblyös, and Ad P Ijzerman
October 2015, Biochemical pharmacology,
Copied contents to your clipboard!